Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.

Juan, O; Popat, S

View/Open

Supporting information (63.31Kb)

Publication Date

2017-02

ICR Author

Popat, Sanjay

Marsden,

Author

Juan, O

Popat, S

Type

Journal Article

Subject

Crizotinib

Non-small cell lung cancer

ROS1 fusions

Targeted therapy

Biomarkers, Tumor

Carcinoma, Non-Small-Cell Lung

Crizotinib

Genetic Testing

Humans

Lung Neoplasms

Molecular Targeted Therapy

Neoplasm Staging

Protein Kinase Inhibitors

Protein-Tyrosine Kinases

Proto-Oncogene Proteins

Pyrazoles

Pyridines

Treatment Outcome

Research team

Thoracic Oncology

Language

eng

Date accepted

2016-11-10

License start date

2017-02

Citation

Lung Cancer, 2017, 104 pp. 131 - 133

Publications Repository